Risk of Severe Abnormal Uterine Bleeding Associated with Rivaroxaban Compared with Apixaban, Dabigatran and Warfarin.

Efe EworukeLaura HouRongmei ZhangHui-Lee WongPeter WaldronAbby AndersonAudrey GassmanDavid MoenyTing-Ying Huang

Published in: Drug safety (2021)

Our study found increased SAUB risk with rivaroxaban use compared with other DOACs or warfarin. Increased risk with rivaroxaban was present among women without underlying gynecological conditions. Women on anticoagulant therapy should be aware of a risk of SAUB.

Keyphrases

atrial fibrillation
direct oral anticoagulants
venous thromboembolism
polycystic ovary syndrome
oral anticoagulants
pregnancy outcomes
breast cancer risk
cervical cancer screening
early onset
metabolic syndrome
insulin resistance
stem cells
type diabetes
bone marrow
smoking cessation